EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ubiquitin B, Ubiquitin C, and β-Catenin as Promising Diagnostic and Prognostic Tools in Prostate Cancer

Daria Piątkowska iD, Anna Klimaszewska-Wiśniewska iD, Alicja Kosińska, Radosław Wujec, Dariusz Grzanka iD, Justyna Durślewicz iD

Cancers · 23.02.2024 · 16 (5) · 902

DOI: 10.3390/cancers16050902 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 23.02.2024. Verfasst von Daria Piątkowska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszc…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nicolaus Copernicus University, Nicolaus Copernicus University in Toruń.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) is a major global public health concern, imposing a significant burden on men and ranking as the second most prevalent malignancy. This study delves into the intricate world of ubiquitination processes and expression regulation, with a specific focus on understanding the roles of ubiquitin B (UBB), ubiquitin C (UBC), and β-Catenin in PC development. We thoroughly analyze the expression profiles of UBB, UBC, and β-Catenin, investigating their interactions and associations with clinical and histopathological data. These findings offer valuable insights into their potential as robust prognostic markers and their significance for patient survival. Our research uncovers the upregulation of UBB and UBC expression in PC tissues, and an even more pronounced expression in lymph node metastases, highlighting their pivotal roles in PC progression. Moreover, we identify a compelling correlation between high UBB and UBC levels and diminished overall survival in PC patients, emphasizing their clinical relevance. Additionally, we observe a significant reduction in membranous β-Catenin expression in PC tissues. Importantly, abnormal β-Catenin expression is strongly associated with shorter survival in PC patients and serves as a significant, independent prognostic factor for patient outcomes. Kaplan–Meier survival analysis indicates that patients with tumors characterized by simultaneous UBB and aberrant β-Catenin expression exhibit the poorest overall survival. These collective insights underline the clinical importance of evaluating UBB, UBC, and β-Catenin as combined prognostic markers in PC.

Schlagwörter

Stichwörter der Autor:innen

UBBUBCprognostic markersprostate cancerubiquitinationβ-Catenin

Autor:innen und Institutionen

  • Department of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland.

ORCID-Profile: Daria Piątkowska, Anna Klimaszewska-Wiśniewska, Dariusz Grzanka, Justyna Durślewicz

Förderung

  • Nicolaus Copernicus University
  • Nicolaus Copernicus University in Toruń

Zitieren

APA

Piątkowska, D., Klimaszewska-Wiśniewska, A., Kosińska, A., Wujec, R., Grzanka, D., & Durślewicz, J. (2024). Ubiquitin B, Ubiquitin C, and β-Catenin as Promising Diagnostic and Prognostic Tools in Prostate Cancer. Cancers, 16(5), 902. https://doi.org/10.3390/cancers16050902

Vancouver

Piątkowska D, Klimaszewska-Wiśniewska A, Kosińska A, Wujec R, Grzanka D, Durślewicz J. Ubiquitin B, Ubiquitin C, and β-Catenin as Promising Diagnostic and Prognostic Tools in Prostate Cancer. Cancers. 2024;16(5):902. doi:10.3390/cancers16050902

BibTeX
@article{Pitkowska2024,
  author = {Piątkowska, Daria and Klimaszewska-Wiśniewska, Anna and Kosińska, Alicja and Wujec, Radosław and Grzanka, Dariusz and Durślewicz, Justyna},
  title = {Ubiquitin B, Ubiquitin C, and β-Catenin as Promising Diagnostic and Prognostic Tools in Prostate Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {5},
  pages = {902},
  doi = {10.3390/cancers16050902}
}
Kostenlos starten →